These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20671520)

  • 21. Sjögren's syndrome.
    Rhodus NL
    Quintessence Int; 1999 Oct; 30(10):689-99. PubMed ID: 10765853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of Disease: primary Sjögren's syndrome and the type I interferon system.
    Nordmark G; Alm GV; Rönnblom L
    Nat Clin Pract Rheumatol; 2006 May; 2(5):262-9. PubMed ID: 16932699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias.
    Tzioufas AG; Voulgarelis M
    Best Pract Res Clin Rheumatol; 2007 Dec; 21(6):989-1010. PubMed ID: 18068857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An important role for B-cell activation factor and B cells in the pathogenesis of Sjögren's syndrome.
    Mackay F; Groom JR; Tangye SG
    Curr Opin Rheumatol; 2007 Sep; 19(5):406-13. PubMed ID: 17762603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging biological therapies in primary Sjogren's syndrome.
    Ramos-Casals M; Brito-Zerón P
    Rheumatology (Oxford); 2007 Sep; 46(9):1389-96. PubMed ID: 17586555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjögren's syndrome.
    Saraux A
    Autoimmun Rev; 2010 Jul; 9(9):609-14. PubMed ID: 20452466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of B cell-targeted therapies in Sjögren's syndrome.
    Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
    Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathophysiology of Sjögren's syndrome].
    Mariette X
    Ann Med Interne (Paris); 2003 May; 154(3):157-68. PubMed ID: 12910042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sjögren's syndrome: Old and new therapeutic targets.
    Mavragani CP; Moutsopoulos HM
    J Autoimmun; 2020 Jun; 110():102364. PubMed ID: 31831255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to assess treatment efficacy in Sjögren's syndrome?
    Vissink A; Bootsma H; Kroese FG; Kallenberg CG
    Curr Opin Rheumatol; 2012 May; 24(3):281-9. PubMed ID: 22450393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on infections and vaccinations in systemic lupus erythematosus and Sjögren's syndrome.
    Pasoto SG; Ribeiro AC; Bonfa E
    Curr Opin Rheumatol; 2014 Sep; 26(5):528-37. PubMed ID: 25022358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sjögren's syndrome in the elderly].
    Gentric-Tilly A
    Ann Med Interne (Paris); 2002 Oct; 153(6):378-82. PubMed ID: 12486386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenesis and treatment of Sjögren's syndrome.
    Fox RI; Maruyama T
    Curr Opin Rheumatol; 1997 Sep; 9(5):393-9. PubMed ID: 9309194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Secondary Gougerot-Sjogren syndrome].
    Sauvezie B; Tournadre A; Chamard C; Dubost JJ
    Rev Prat; 2001 Jan; 51(2):171-6. PubMed ID: 11252943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy.
    Hansen A; Lipsky PE; Dörner T
    Curr Opin Rheumatol; 2005 Sep; 17(5):558-65. PubMed ID: 16093833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salivary gland changes in the NOD mouse model for Sjögren's syndrome: is there a non-immune genetic trigger?
    Humphreys-Beher MG; Yamachika S; Yamamoto H; Maeda N; Nakagawa Y; Peck AB; Robinson CP
    Eur J Morphol; 1998 Aug; 36 Suppl():247-51. PubMed ID: 9825931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review and update of Sjögren's syndrome: manifestations, diagnosis, and treatment.
    Carsons S
    Am J Manag Care; 2001 Sep; 7(14 Suppl):S433-43. PubMed ID: 11605978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibodies to Epstein-Barr virus and cytomegalovirus in primary Sjogren's syndrome.
    Origgi L; Hu C; Bertetti E; Asero R; D'Agostino P; Radelli L; Riboldi P
    Boll Ist Sieroter Milan; 1988; 67(4):265-74. PubMed ID: 2856043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis of Sjögren's syndrome.
    Nikolov NP; Illei GG
    Curr Opin Rheumatol; 2009 Sep; 21(5):465-70. PubMed ID: 19568172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Possible involvement of Epstein-Barr virus in the pathogenesis of Sjögren's syndrome].
    Haruta J; Saito I
    Nihon Rinsho; 1995 Oct; 53(10):2479-83. PubMed ID: 8531359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.